# LENZ Therapeutics (LENZ) — News

LENZ · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lenz/news

## Recent headlines

- [LONZA upgrades organic growth model with mid term targets](https://www.ainvest.com/news/lonza-upgrades-organic-growth-model-mid-term-targets-2610) — AInvest Wire, Oct 14, 2026
  Lonza has confirmed its mid-term strategic direction following a strong first-half performance in 2024, with the company maintaining its upgraded guidance for the 2024–2028 period. The Swiss-based contract development and manufacturing organization (CDMO) reported sales of CHF 3.1 billion in the…
- [Lenz Therapeutics, Inc.: BofA Global Research cuts to neutral from buy; cuts price objective to $7 from $31](https://www.ainvest.com/news/lenz-therapeutics-bofa-global-research-cuts-neutral-buy-cuts-price-objective-7-31-2608) — AInvest Wire, Aug 13, 2026
  Bank of America Global Research has revised its stance on Lenz Therapeutics, Inc. (Nasdaq: LENZ), downgrading the stock from "Buy" to "Neutral" and reducing its price target from $31 to $7 as of August 13, 2026. This adjustment follows a reassessment of the company’s growth trajectory, particularly…
- [CStone enters into commercialization pact with Arrotex](https://www.ainvest.com/news/cstone-enters-commercialization-pact-arrotex-2606) — AInvest Wire, Jun 25, 2026
  CStone Pharmaceuticals (HKEX: 2616) has not entered into a commercialization agreement with Arrotex for any of its drug candidates as of the latest available information. However, Arrotex Pharmaceuticals has recently entered into an exclusive license and commercialization agreement with LENZ…
- [Lenz Thera, Arrotx Pharma get license & commercialization pact](https://www.ainvest.com/news/lenz-thera-arrotx-pharma-license-commercialization-pact-2606) — AInvest Wire, Jun 24, 2026
  LENZ Therapeutics, Inc. (Nasdaq: LENZ) has entered into an exclusive license and commercialization agreement with Laboratoires Théa for the registration and commercialization of LNZ100 in Canada for the treatment of presbyopia. Under the terms of the agreement, LENZ is eligible to receive over $70…
- [Lenz Therapeutics - to receive upfront payment and profit share from Arrotex Vizz sales](https://www.ainvest.com/news/lenz-therapeutics-receive-upfront-payment-profit-share-arrotex-vizz-sales-2606) — AInvest Wire, Jun 24, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).